Design and engineering of novel genetic vectors

Kano Therapeutics is pioneering a novel approach to gene editing through the use of circular single-stranded DNA (ssDNA) as a genetic payload. This innovative biomaterial combines the stability of double-stranded DNA with the flexibility of RNA, making it an ideal candidate for therapeutic applications. The company’s fermentation-based production technique allows for the creation of gene-length ssDNA templates, which are designed to enhance the precision and efficiency of gene insertion. By utilizing ssDNA, Kano aims to achieve higher site-specific knock-in efficiencies while minimizing off-target effects and immune activation, thereby providing a safer alternative for genome editing compared to traditional methods.

The platform developed by Kano Therapeutics integrates design, manufacturing, and screening processes to streamline the development of optimized DNA templates. This comprehensive approach addresses key challenges in the field, such as manufacturing bottlenecks and the need for longer DNA insertions. By being indication-, disease-, and technology-agnostic, Kano is positioned to make a significant impact across various therapeutic areas. The company is also focused on building a databank that links ssDNA sequence design to activity, which is expected to accelerate development timelines and reduce costs for collaborative gene replacement therapies.

United States

Kano Therapeutics is a founder-led biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of technology.

Kano Therapeutics

Company Details